Business

After securing $2.1 billion this May, AI-driven drug designer Isomorphic Labs is back with more money—a lot more—securing the industry’s largest private fundraise ever.
FEATURED STORIES
Women held 29% of biotech board seats in fiscal year 2025 but just 8.8% of CEO roles, highlighting uneven progress across industry leadership spots.
BridgeBio has produced two young leaders on BioSpace’s 2026 40 Under 40 list. Morgan Paull and Christine Zhang attribute their early success to the company’s unique hub-and-spoke model and a drive to help patients with few treatment options. “It’s very personal,” Paull said.
When Ionis Pharmaceuticals’ Tryngolza undersold, investors immediately looked to Arrowhead Pharmaceuticals’ executives for answers on how they will navigate a launch in the same market.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
M&A
Blackstone will provide $750 million for Phase 3 development of Ollin Biosciences’ retinal disease bispecific as Johnson & Johnson looks to bolster its eye therapeutics pipeline after several setbacks.
Eli Lilly’s business development team has inked 14 buyouts this year so far, with Calytrix Bio tucking into the pharma’s oncology pipeline.
Companies at BIO-Europe said shifting U.S. politics have created an opening to promote Canada’s strengths to European partners.
To achieve a positive return, drugs launched from 2016 to 2020 must generate nearly $12 billion in sales, up from just $1.4 billion for drugs launched in the early 1990s.
Backed by Novartis’ venture arm, Eli Lilly and CRISPR Therapeutics, Seawolf is advancing its nonviral DNA delivery platform while inking a pact with Sanofi.
Cellectis’ business transformation could cost around 160 global employees their jobs. The company has stopped enrollment in its two CAR T programs as it focuses on trials of its in vivo candidates.
Less than two years after acquiring the assets, Lantheus is selling its CDMO unit and a New Jersey production plant to PharmaLogic.
IPO
Windward Bio’s public debut brings this year’s IPO count well above the sluggish total of eight in 2025.
Regeneron’s mid-stage success in postural orthostatic tachycardia syndrome has the company gearing up to launch a Phase 3 study in the first half of 2027.
Addex Therapeutics spinout Neurosterix will use the series B funds to advance an oral drug targeting M4, a muscarinic receptor also targeted by BMS’ Cobenfy, which introduced a new mechanism for treating schizophrenia with its 2024 approval.